Development of an MgluR4 PET Radioligand
Research Grant, 2014
Study Rationale: † † † † † † † † ††
mGluR4 is a glutamate receptor that is believed to be a potential therapeutic target for Parkinsonís disease (PD). Developing an imaging tracer may allow researchers to quantify this receptor in subjects with the disease. In addition a tracer will be critical in determining dosing of drugs that are developed toward this target.
We hypothesize that a radiolabeled compound will allow researchers to measure the quantity of the mglur4 receptor in pre-clinical models.
From research performed by Prexton Therapeutics, a large number of compounds with high affinity have been discovered. We will label with Fluorine-18 the compounds with the best affinity and using a PET scanner to evaluate their distribution pre-clinically.
Impact on Diagnosis/Treatment of Parkinsonís Disease: † † † † † ††
While a decrease in dopamine is the most recognized neurochemical change in the brain in PD, studies have recently shown that other non-dopamine neurochemicals also play an important role. The development of an imaging tracer for mGlur4 will provide an extremely useful tool to improve our understanding of the role of the glutaminergic pathway in individuals with PD and will be a critical component of drug development. †
Next Steps for Development:
After screening and identifying the best compound in pre-clinical models, we will perform test/retest and dose occupancy studies.
CEO at Prexton Therapeutics
Location: Geneva, Switzerland
Vice President of Chemistry and Translational Research at Molecular NeuroImaging
Laboratory Research and Development Director at Institute for Neurodegenerative Disorders
Location: New Haven, Connecticut, United States